Lipid-Lowering Agents.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30702996.
- Also identified by DOI 10.1161/CIRCRESAHA.118.313171.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several new or emerging drugs for dyslipidemia owe their existence, in part, to human genetic evidence, such as observations in families with rare genetic disorders or in Mendelian randomization studies. Much effort has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and Lp[a] (lipoprotein[a]), with some sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol. Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol. Alipogene tiparvovec, pradigastat, and volanesorsen primarily target elevated triglycerides, whereas evinacumab and IONIS-ANGPTL3-L<sub>Rx</sub> target both LDL cholesterol and triglyceride. IONIS-APO(a)-L<sub>Rx</sub> targets Lp(a).
Medical subject headings
- Dyslipidemias
- Hypolipidemic Agents